Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder.
Antimuscarinic medications are the first-line pharmacological treatment for overactive bladder (OAB); however, little is known about the utilization pattern of antimuscarinic agents in elderly patients with OAB.



This study examined the prevalence and predictors of antimuscarinic medication prescribing in elderly patients with OAB, using national ambulatory survey data.



This cross-sectional study utilized the 2009-2010 National Ambulatory Medical Care Survey and the outpatient component of the National Hospital Ambulatory Medical Care Survey. The study included patients aged ≥65 years diagnosed with OAB based on the International Classification of Diseases. Antimuscarinic medications were operationally defined using the American Hospital Formulary Service classification and identified using Multum Lexicon codes. Descriptive statistics using sampling weights were used to estimate the prevalence of antimuscarinic medication prescription, while multivariable logistic regression within the conceptual framework of the Anderson Behavioral Model was used to identify the factors associated with antimuscarinic medication prescription in elderly patients with OAB.



According to the national surveys, 2.18 million (95 % confidence interval [CI] 1.62-2.75) elderly outpatient visits were made for OAB, of which 0.90 million (41.43 %) visits involved prescribing of antimuscarinic medications. The most frequently prescribed drugs were solifenacin (14.25 %), oxybutynin (10.50 %), and tolterodine (6.89 %). Multivariable analysis revealed that patients ≥85 years of age (odds ratio [OR] 3.50, 95 % CI 1.23-9.92) were more likely to receive antimuscarinic medications, and the South region (OR 2.78, 95 % CI 1.01-7.66) increased the likelihood of receiving antimuscarinic medications in elderly patients with OAB.



This study found that antimuscarinic medications are commonly prescribed for elderly patients with OAB and there is variation in antimuscarinic use across age and region.
Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Texas Medical Center, 1441 Moursund Street, Houston, TX, 77030, USA.
Nandita
N
Kachru
Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Texas Medical Center, 1441 Moursund Street, Houston, TX, 77030, USA.
Sneha
S
Sura
Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Texas Medical Center, 1441 Moursund Street, Houston, TX, 77030, USA.
Satabdi
S
Chatterjee
Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Texas Medical Center, 1441 Moursund Street, Houston, TX, 77030, USA. raparasu@central.uh.edu.
Rajender R
RR
Aparasu
D000368:Aged; D015897:Comorbidity; D003430:Cross-Sectional Studies; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D004363:Drug Utilization / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010045:Outpatients; D015995:Prevalence; D012189:Retrospective Studies; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000453:epidemiology
D018727:Muscarinic Antagonists
Neurourol Urodyn. 2014 Jan;33(1):17-30
24127366
J Urol. 2005 Feb;173(2):493-8
15643227
Arch Intern Med. 2008 Mar 10;168(5):508-13
18332297
Int J Clin Pract. 2010 Aug;64(9):1279-86
20529135
Urology. 2004 Dec;64(6 Suppl 1):2-6
15621220
Eur Urol. 2005 Jul;48(1):5-26
15885877
Arch Intern Med. 2003 Aug 11-25;163(15):1813-20
12912717
J Am Pharm Assoc (2003). 2013 Sep-Oct;53(5):496-504
24030127
World J Urol. 2003 May;20(6):327-36
12811491
Int J Clin Pract. 2006 Aug;60(8):949-58
16893437
Am J Med. 2006 Mar;119(3 Suppl 1):29-36
16483866
Vital Health Stat 1. 1994 Jul;(34):1-78
7975355
Neurourol Urodyn. 2002;21(2):167-78
11857671
J Health Soc Behav. 1995 Mar;36(1):1-10
7738325
Urology. 2010 Mar;75(3):526-32, 532.e1-18
20035977
J Am Med Dir Assoc. 2013 Oct;14(10):749-60
23639715
Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003781
17054185
Int Urogynecol J. 2014 Apr;25(4):479-84
24158462
Pharmacotherapy. 2005 Apr;25(4):511-9
15977912
BMJ. 2012 Apr 17;344:e2365
22511208
Drugs Aging. 1993 Jul-Aug;3(4):335-48
8369593
BJU Int. 2007 Mar;99(3):502-9
17407511
Int Urogynecol J Pelvic Floor Dysfunct. 2009 Nov;20(11):1285-91
19636490
Urologiia. 2015 Jul-Aug;(4):121-4
26665779
PLoS One. 2011 Feb 23;6(2):e16718
21373193
Am J Geriatr Pharmacother. 2006 Mar;4(1):14-24
16730617
J Am Geriatr Soc. 2015 Nov;63(11):2298-307
26503458
Curr Med Res Opin. 2016;32(1):123-31
26455537
Milbank Mem Fund Q Health Soc. 1973 Winter;51(1):95-124
4198894
Chin Med J (Engl). 2014;127(2):261-5
24438613
J Clin Pharmacol. 2006 Dec;46(12):1481-6
17101747
Clin Ther. 2005 Jan;27(1):127-38; quiz 139-40
15763613
Am J Manag Care. 2009 Mar;15(4 Suppl):S90-7
19355803
N Engl J Med. 2010 Sep 16;363(12):1156-62
20843250
J Am Pharm Assoc (2003). 2008 Mar-Apr;48(2):203-11; 3 p following 211
18359733
Drugs Aging. 2015 Oct;32(10):835-48
26442862
Lancet Neurol. 2004 Jan;3(1):46-53
14693111
Urology. 2016 Jan;87:64-9
26436212
Auton Autacoid Pharmacol. 2002 Jun;22(3):133-45
12452898
Aust Fam Physician. 2012 Nov;41(11):878-83
23145420
J Urol. 2012 Dec;188(6 Suppl):2455-63
23098785
Curr Med Res Opin. 2016;32(4):621-38
26828974
Am J Manag Care. 2000 Jul;6(11 Suppl):S580-90
11183901
Urology. 2000 May;55(5A Suppl):33-46; discussion 50
10767450
J R Soc Med. 2000 Sep;93(9):457-62
11089480